These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 16283310)

  • 1. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance.
    Stordal B; Peters G; Davey R
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1094-105. PubMed ID: 16967470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
    Ekblad L; Kjellström J; Johnsson A
    Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding cisplatin resistance using cellular models.
    Stordal B; Davey M
    IUBMB Life; 2007 Nov; 59(11):696-9. PubMed ID: 17885832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
    Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
    Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.
    Stordal B; Davey R
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):661-72. PubMed ID: 18575867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
    Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
    Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular models of drug- and radiation-resistant small cell lung cancer.
    Davey RA; Locke VL; Henness S; Harvie RM; Davey MW
    Anticancer Res; 2004; 24(2A):465-71. PubMed ID: 15152945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines.
    Kashiwagi E; Izumi H; Yasuniwa Y; Baba R; Doi Y; Kidani A; Arao T; Nishio K; Naito S; Kohno K
    Cancer Sci; 2011 Feb; 102(2):382-6. PubMed ID: 21087353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
    Kasahara K; Fujiwara Y; Nishio K; Ohmori T; Sugimoto Y; Komiya K; Matsuda T; Saijo N
    Cancer Res; 1991 Jun; 51(12):3237-42. PubMed ID: 1645616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin: mechanism of action and antineoplastic activity.
    Raymond E; Faivre S; Woynarowski JM; Chaney SG
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
    Basu A; Weixel K; Saijo N
    Cell Growth Differ; 1996 Nov; 7(11):1507-12. PubMed ID: 8930400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of cytotoxicities of platinum compounds.
    Goodisman J; Hagrman D; Tacka KA; Souid AK
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
    Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
    Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of oxaliplatin against human tumor colony-forming units.
    Raymond E; Lawrence R; Izbicka E; Faivre S; Von Hoff DD
    Clin Cancer Res; 1998 Apr; 4(4):1021-9. PubMed ID: 9563898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.